Stammdaten
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
Unternehmen & Branche
| Name | Lite Strategy, Inc. |
|---|---|
| Ticker | LITS |
| CIK | 0001262104 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | – |
| Marktkapitalisierung | 41,6 Mio. USD |
| Beta | 0,10 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | -30,799,000 | -0.82 | 82,937,000 | 81,850,000 | |
| 2025-09-30 | 10-Q | -3,639,000 | -0.12 | 113,337,000 | 112,269,000 | |
| 2025-06-30 | 10-K | 0 | -15,945,000 | -2.39 | 18,285,000 | 16,931,000 |
| 2025-03-31 | 10-Q | 0 | -2,573,000 | -0.39 | 20,779,000 | 19,541,000 |
| 2024-12-31 | 10-Q | 0 | -2,677,000 | -0.40 | 24,385,000 | 22,098,000 |
| 2024-09-30 | 10-Q | 0 | -8,007,000 | -1.20 | 27,750,000 | 24,878,000 |
| 2024-06-30 | 10-K | 65,297,000 | 17,778,000 | 2.67 | 41,375,000 | 33,020,000 |
| 2024-03-31 | 10-Q | 0 | -9,127,000 | -1.37 | 71,260,000 | 51,029,000 |
| 2023-12-31 | 10-Q | 0 | -11,063,000 | -1.66 | 78,538,000 | 59,488,000 |
| 2023-09-30 | 10-Q | 65,297,000 | 56,374,000 | 8.46 | 101,251,000 | 81,361,000 |
| 2023-06-30 | 10-K | 48,816,000 | -32,000,000 | -4.78 | 120,809,000 | 24,624,000 |
| 2023-03-31 | 10-Q | 5,894,000 | -15,438,000 | -2.32 | 134,187,000 | 34,354,000 |
| 2022-12-31 | 10-Q | 32,735,000 | 10,253,000 | 1.54 | 147,599,000 | 48,374,000 |
| 2022-09-30 | 10-Q | 8,730,000 | -16,624,000 | -2.49 | 163,583,000 | 37,308,000 |
| 2022-06-30 | 10-K | 40,697,000 | -54,454,000 | -9.99 | 177,840,000 | 52,413,000 |
| 2022-03-31 | 10-Q | 9,694,000 | -8,725,000 | -1.31 | 194,429,000 | 67,806,000 |
| 2021-12-31 | 10-Q | 11,832,000 | -12,156,000 | -0.14 | 209,464,000 | 73,334,000 |
| 2021-09-30 | 10-Q | 7,757,000 | -17,510,000 | -0.18 | 176,351,000 | 34,301,000 |
| 2021-06-30 | 10-K | 34,796,000 | -41,314,000 | -0.60 | 174,098,000 | 49,466,000 |
| 2021-03-31 | 10-Q | 8,109,000 | -25,622,000 | -0.23 | 186,122,000 | 55,728,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-19 | Flynn James P | Director | Open Market Purchase | 70,000 | 1.40 | 97,699.00 | +162,2% | |
| 2025-11-19 | Flynn James P | Director | Open Market Purchase | 12,100 | 1.88 | 22,777.04 | +37,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.